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OBJECTIVE — Tocomparerisksoflower-extremityamputationbetweenpatientswithChar-
cot arthropathy and those with diabetic foot ulcers.
RESEARCH DESIGN AND METHODS — A retrospective cohort of patients with in-
cidentCharcotarthropathyordiabeticfootulcersin2003wasfollowedfor5yearsforanymajor
and minor amputations in the lower extremities.
RESULTS — After a mean follow-up of 37  20 and 43  18 months, the Charcot and ulcer
groups had 4.1 and 4.7 amputations per 100 person-years, respectively. Among patients 65
years old at the end of follow-up, amputation risk relative to patients with Charcot alone was 7
times higher for patients with ulcer alone and 12 times higher for patients with Charcot and
ulcer.
CONCLUSIONS — Charcot arthropathy by itself does not pose a serious amputation risk,
butulcercomplicationmultiplicativelyincreasestherisk.EarlysurgicalinterventionforCharcot
patients in the absence of deformity or ulceration may not be advisable.
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D
iabetic foot ulcers are serious
threats to the foot (1–4). Amputa-
tion risks of Charcot arthropathy is
less clear, but previous studies suggest
that it is a less serious but signiﬁcant risk
for lower-limb amputation (5). Our ob-
jective is to compare the amputation risk
of Charcot arthropathy to that of diabetic
foot ulcer using a nationwide diabetic
population treated in the Department of
Veterans Affairs (VA).
RESEARCH DESIGN AND
METHODS— From a national dia-
beticpopulationtreatedintheVAin2003
(6,7), we identiﬁed patients who were
newly diagnosed with Charcot arthropa-
thy (International Classiﬁcation of Diseases,
Ninth Revision, Clinical Modiﬁcation [ICD-
9-CM] 713.5) and with a diabetic foot ul-
cer (707.1x or 707.9) but without
Charcot arthropathy in the years 2002–
2007. In both groups, a condition was
determinedasnewlydiagnosedin2003if
itwasnotfoundinanyutilizationrecords
in 2002. We used 2002 as a full-year
washout period (8).
Major and minor amputations were
identiﬁed from the VA inpatient and out-
patientrecordsusingICD-9-CMandCur-
rent Procedural Terminology (CPT)-4
codes (foot, 84.10–84.12, 28800–
28825; ankle or leg, 84.13–84.15,
27880–27889; knee or above, 84.16–
84.17, 27590–27598). Data for known
risk factors of amputation including age,
sex,race,maritalstatus,diabetesduration
and control, and all coexisting conditions
intheElixhausercomorbiditymethod(9)
were obtained from patient records for
2003.
We computed the time to event by
following patients in either group from
the date of the ﬁrst diagnosis for up to 5
years to the ﬁrst date of amputation and
analyzed it using Cox proportional haz-
ards regression.
Our initial analysis suggested that
amputation risks were not signiﬁcantly
different between the two groups but that
Charcot patients with foot ulceration had
remarkably higher risks than individuals
without. We thus stratiﬁed the study co-
hort into three groups (patients with
Charcot alone, patients with Charcot and
foot ulcers, and patients with foot ulcers
alone) and compared amputation risks
forpatientsinthethreegroups.ForMedi-
care beneﬁciaries, some amputations
might have been performed in non-VA
hospitals and were not observable in the
VA data. We therefore analyzed the data
separately for patients who were 65
years old at the end of follow-up and pa-
tientswhowere65yearsold.Thisstudy
was approved by our institutional review
board.
RESULTS— FromtheVAcohortofdi-
abetic patients in 2003, we identiﬁed 911
patients with incident Charcot arthropa-
thy and 15,117 patients with incident di-
abetic foot ulcers after eliminating
patients with previous history of lower-
extremity amputations. Crude amputa-
tion rates were 14.7% for Charcot
patientsand14.5%forfootulcerpatients.
After a mean follow-up of 37  20 and
43  18 months for Charcot and ulcer
groups, respectively, patients with Char-
cot arthropathy experienced 4.1 amputa-
tions per 100 person-years compared
with 4.7 for patients with diabetic foot
ulcers (Mantel-Haenszel rate ratio 
0.88; P  0.15).
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were treated for foot ulceration between
2002 and 2007; 66% (354 patients) were
treated for foot ulceration immediately
before or concurrently with Charcot ar-
thropathy, and 34% (184 patients) expe-
rienced it as a complication. Compared
with patients with Charcot alone, those
with ulcer alone had 7 times higher risk
and those with both an ulcer and Charcot
had 12 times higher risk of amputation
amongpatients65years(Table1).Sim-
ilarly, the two groups had 9 and 13 times
higherrisksthanthereferenceforpatients
65 years old.
CONCLUSIONS — Ourresultsshow
that amputation risk for Charcot arthrop-
athy overall is not signiﬁcantly different
from that for diabetic foot ulcers. When
Charcot patients were stratiﬁed by foot
ulceration, Charcot alone was associated
withlowrisk(2%)andulcerationswere
responsible for most amputations experi-
enced by Charcot patients.
These results are consistent with the
current practice guideline suggesting that
prevention of ulceration is critical for
Charcot limb salvage (10). They further
call into question whether surgery is ad-
visable early in the disease process. Feet
affected by Charcot arthropathy are un-
likely to ulcerate when they remain clini-
cally plantigrade and the radiographic
weight-bearing relationship between the
hindfootandforefootiscollinear(11,12).
Theseresultssuggestthatamputationrisk
for Charcot arthropathy may be reduced
by reserving corrective surgeries for pa-
tients with a high risk of Charcot-related
ulceration.
Our results also suggest that patients
with Charcot arthropathy in the commu-
nity may have considerably higher risk of
amputation than previously believed. The
rate of 6.6% in a meta-analysis mentioned
above represent half the rate observed for
the VA Charcot patients (14.7%). This may
be attributable to the secondary ulceration
rate in this VA cohort (34% during a 5-year
follow-up), which is higher than others
with corrective surgical intervention
(12,13) and comparable to some series re-
ported from specialty clinics (14,15).
Our results are consistent with a pre-
vious study of amputation risks of dia-
betic foot ulcer. Moulik et al. (4) followed
Table 1 —Adjusted hazard ratios from the full Cox proportional hazards regression models on all patients with incident Charcot arthropathy
or foot ulcer stratiﬁed by age at the end of follow-up*
Individuals 65 years old (n  5,392) Individuals 65 years old (n  10,636)
HR (95% CI) P HR (95% CI) P
Comparison groups (Charcot alone)
Diabetic foot ulcer alone 11.161 (4.070–30.605) 0.001 12.983 (4.061–41.511) 0.001
Diabetic foot ulcer and Charcot 7.297 (2.729–19.513) 0.001 8.846 (2.847–27.484) 0.001
Age
55 years (55) 0.912 (0.801–1.038) 0.163
75–84 years (65–74) 0.864 (0.733–1.019) 0.083
85 years (65–74) 0.728 (0.612–0.867) 0.001
Race/ethnicity (non-Hispanic white)
Non-Hispanic black 1.053 (0.890–1.246) 0.544 1.276 (1.105–1.474) 0.001
Hispanic 0.875 (0.634–1.206) 0.415 1.180 (0.871–1.597) 0.285
Other/unknown 0.988 (0.833–1.172) 0.890 1.198 (0.924–1.555) 0.173
Male (female) 1.870 (1.078–3.244) 0.026 1.354 (0.764–2.399) 0.299
Married (not married) 0.723 (0.635–0.824) 0.001 0.870 (0.779–0.971) 0.013
Diabetes duration 6 years 1.120 (0.978–1.284) 0.102 1.303 (1.166–1.456) 0.001
A1C 9% 1.539 (1.342–1.766) 0.001 1.340 (1.138–1.579) 0.001
BMI (25 kg/m
2)
25–30 0.798 (0.637–0.999) 0.049 0.691 (0.582–0.819) 0.001
30–35 0.548 (0.438–0.686) 0.001 0.479 (0.400–0.575) 0.001
35 0.299 (0.212–0.422) 0.001 0.212 (0.139–0.325) 0.001
Unmeasured 0.577 (0.471–0.707) 0.001 0.650 (0.556–0.759) 0.001
Comorbidities†
Peripheral vascular disease 1.880 (1.636–2.161) 0.001 2.324 (2.083–2.592) 0.001
Congestive heart failure 1.263 (1.023–1.558) 0.030 1.319 (1.145–1.520) 0.001
Paralysis 0.919 (0.643–1.314) 0.643 1.307 (1.018–1.679) 0.036
Renal failure 1.549 (1.257–1.909) 0.001 1.272 (1.080–1.498) 0.004
Liver disease 0.868 (0.637–1.182) 0.368 0.755 (0.449–1.270) 0.289
Coagulopathy 0.699 (0.417–1.172) 0.174 0.673 (0.454–0.998) 0.049
Weight loss 1.368 (0.935–2.002) 0.107 1.423 (1.041–1.943) 0.027
Fluid and electrolyte disorder 1.349 (1.097–1.659) 0.005 1.246 (1.038–1.496) 0.018
Blood loss 2.649 (1.272–5.519) 0.009 1.260 (0.703–2.259) 0.438
Deﬁciency anemias 1.053 (0.849–1.306) 0.640 1.169 (1.004–1.360) 0.044
Alcohol abuse 1.042 (0.815–1.333) 0.744 1.398 (1.008–1.939) 0.045
Depression 0.950 (0.791–1.141) 0.584 0.776 (0.630–0.955) 0.017
*Reference categories are in brackets. †All comorbidities in the Elixhauser method were included, except conditions common to all patients in the cohort (diabetes
with or without chronic complications) were included in the models. Only conditions that were statistically signiﬁcant at 0.05 in either model are shown.
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28 months and reported a 5-year rate of
19%. The VA cohort consisting of foot
ulcer patients, who were overall older
than the Moulik et al. sample, had a
5-year rate of 20%.
One limitation of this study is that it
reliedonpatientdatarecordedforadmin-
istrative purposes. Regarding the accu-
racy of data, our chart reviews suggest
that diabetic foot ulcers can be identiﬁed
from administrative data with 93% sensi-
tivity and 91% speciﬁcity. We also con-
ﬁrmedthepresenceofCharcotarthropathy
for12of13patients(92%)throughmedical
records. Importantly, however, we could
notlinktheaffectedlimbatstudyentrywith
the limb amputated during follow-up be-
cause of the lack of information in ICD-
9-CMcodes.Also,wedidnothaveaccessto
data for Medicare use by elderly VA users,
and some amputations performed in the
non-VA hospitals could not be observed.
For this reason, the ﬁndings for patients
aged 65 years need to be interpreted
carefully.
In summary, diabetic foot ulcers pose
a signiﬁcant risk for amputation, while
Charcot arthropathy does not unless it is
complicatedbyanulcer.Furtherresearch
is needed to evaluate comparative effec-
tiveness of corrective surgery versus ac-
commodative treatments in preventing
amputationsforCharcotpatients(10,13).
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